Published in Cell Immunol on August 01, 1992
Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer (2011) 1.20
Increase of circulating gamma/delta T lymphocytes in the peripheral blood of patients affected by active inflammatory bowel disease. Clin Exp Immunol (1994) 1.15
Licensing of γδT cells for professional antigen presentation: A new role for antibodies in regulation of antitumor immune responses. Oncoimmunology (2012) 0.81
Decreased expression of FcgammaRIII (CD16) by gammadelta T cells in patients with rheumatoid arthritis. Immunology (2000) 0.79
Cytomegalovirus-responsive γδ T cells: novel effector cells in antibody-mediated kidney allograft microcirculation lesions. J Am Soc Nephrol (2014) 0.78
Relevance of Fc gamma RIIIa-158V-F polymorphism to recurrence of adult periodontitis in Japanese patients. Clin Exp Immunol (1999) 0.77
Interleukin-10 from T cells, but not macrophages and granulocytes, is required for chronic disease in Leishmania mexicana infection. Infect Immun (2015) 0.75
Human γδ T cells augment antigen presentation in Listeria Monocytogenes infection. Mol Med (2016) 0.75
Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies. Oncoimmunology (2016) 0.75
A T-cell receptor gamma/CD3 complex found on cloned functional lymphocytes. Nature (1987) 3.81
Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity (1996) 2.96
Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol (2001) 2.79
A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol (1991) 2.48
The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J (1997) 2.34
IgA and the IgA Fc receptor. Trends Immunol (2001) 2.05
On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest (1992) 2.04
Independent movement of IgD and IgM molecules on the surface of individual lymphocytes. J Immunol (1973) 2.03
Molecular basis for a polymorphism of human Fc gamma receptor II (CD32). J Exp Med (1990) 1.79
Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J Virol (2001) 1.64
Distinct molecular forms of human T cell receptor gamma/delta detected on viable T cells by a monoclonal antibody. J Exp Med (1988) 1.62
IgG receptor polymorphisms: risk factors for disease. Immunogenetics (1998) 1.59
Gamma/delta T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis. J Exp Med (1990) 1.50
Murine IgG1 complexes trigger immune effector functions predominantly via Fc gamma RIII (CD16). J Immunol (1998) 1.49
Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies. Immunol Today (1997) 1.48
Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther (2000) 1.46
Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol (2001) 1.41
Regulation of cytolytic activity in CD3- and CD3+ killer cell clones by monoclonal antibodies (anti-CD16, anti-CD2, anti-CD3) depends on subclass specificity of target cell IgG-FcR. J Immunol (1987) 1.40
Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response. J Clin Oncol (1993) 1.39
Fc gamma receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children. J Infect Dis (1994) 1.37
Functional reactivity of WT31 monoclonal antibody with T cell receptor-gamma expressing CD3+4-8- T cells. J Immunol (1988) 1.34
Rapidly expanded activated human killer cell clones have strong antitumor cell activity and have the surface phenotype of either T gamma, T-non-gamma, or null cells. J Immunol (1984) 1.33
Phagocytosis of Staphylococcus aureus and Haemophilus influenzae type B opsonized with polyclonal human IgG1 and IgG2 antibodies. Functional hFc gamma RIIa polymorphism to IgG2. J Immunol (1993) 1.29
Induction and blocking of cytolysis in CD2+, CD3- NK and CD2+, CD3+ cytotoxic T lymphocytes via CD2 50 KD sheep erythrocyte receptor. J Immunol (1986) 1.28
The p85 subunit of phosphatidylinositol 3-kinase associates with the Fc receptor gamma-chain and linker for activitor of T cells (LAT) in platelets stimulated by collagen and convulxin. J Biol Chem (1998) 1.25
Fc gamma receptor IIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections. J Infect Dis (1994) 1.25
Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production. Gene Ther (2000) 1.24
Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils. Infect Immun (1995) 1.24
Functional association between the human myeloid immunoglobulin A Fc receptor (CD89) and FcR gamma chain. Molecular basis for CD89/FcR gamma chain association. J Biol Chem (1995) 1.23
Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice. J Clin Invest (1996) 1.23
Structural and serological heterogeneity of gamma/delta T cell antigen receptor expression in thymus and peripheral blood. Eur J Immunol (1988) 1.22
Immunogenic properties in mice of hexasaccharide from the capsular polysaccharide of Streptococcus pneumoniae type 3. Infect Immun (1983) 1.21
Nontoxigenic strains of Clostridium difficile lack the genes for both toxin A and toxin B. J Clin Microbiol (1991) 1.20
FcalphaRI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity. Nat Med (2000) 1.19
Immunoglobulin A-mediated protection against Bordetella pertussis infection. Infect Immun (2001) 1.19
Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation. Blood (2001) 1.18
Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood (2001) 1.17
FcR gamma-chain is essential for both surface expression and function of human Fc gamma RI (CD64) in vivo. Blood (1996) 1.15
A novel PCR-based method for direct Fc gamma receptor IIIa (CD16) allotyping. J Immunol Methods (2000) 1.15
Structure and function of human IgA Fc receptors (Fc alpha R). Crit Rev Immunol (1996) 1.15
Role of Fc receptor gamma chain in inflammation and cartilage damage during experimental antigen-induced arthritis. Arthritis Rheum (2000) 1.13
Detection of multiple 'Ebnotypes' in individual Epstein-Barr virus carriers following lymphocyte transformation by virus derived from peripheral blood and oropharynx. J Gen Virol (1994) 1.12
Expression of IgG Fc receptor antigens in placenta and on endothelial cells in humans. An immunohistochemical study. Am J Pathol (1991) 1.10
Induction of natural killer cell activity and allocytotoxicity in human peripheral blood lymphocytes after mixed lymphocyte culture. Scand J Immunol (1981) 1.10
Differences in complement activation between complement-resistant and complement-sensitive Moraxella (Branhamella) catarrhalis strains occur at the level of membrane attack complex formation. Infect Immun (1994) 1.10
Human V gamma 9-V delta 2 T cell receptor-gamma delta lymphocytes show specificity to Daudi Burkitt's lymphoma cells. J Immunol (1990) 1.09
Rapid expansion of allospecific cytotoxic T cell clones using nonspecific feeder cell lines without further addition of exogenous IL2. Transplantation (1984) 1.07
Fc receptor-mediated immunity against Bordetella pertussis. J Immunol (2001) 1.07
Modulation of the immune response to pneumococcal type 14 capsular polysaccharide-protein conjugates by the adjuvant Quil A depends on the properties of the conjugates. Infect Immun (1989) 1.07
Clinical relevance of Fc gamma receptor polymorphisms. Ann N Y Acad Sci (1997) 1.07
Human C-reactive protein does not bind to FcgammaRIIa on phagocytic cells. J Clin Invest (2001) 1.07
Penicillin and clindamycin differentially inhibit the production of pyrogenic exotoxins A and B by group A streptococci. Int J Antimicrob Agents (2001) 1.06
Coordinated V gamma and V delta gene segment rearrangements in human T cell receptor gamma/delta+ lymphocytes. Eur J Immunol (1989) 1.06
Three genes for the human high affinity Fc receptor for IgG (Fc gamma RI) encode four distinct transcription products. J Biol Chem (1992) 1.04
Heparin-induced thrombocytopenia: new insights into the impact of the FcgammaRIIa-R-H131 polymorphism. Blood (1998) 1.04
Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival. Int J Cancer (1999) 1.04
Human immunoglobulin A receptor (FcalphaRI, CD89) function in transgenic mice requires both FcR gamma chain and CR3 (CD11b/CD18). Blood (1999) 1.03
Crucial role of FcgammaRIIa (CD32) in assessment of functional anti-Streptococcus pneumoniae antibody activity in human sera. J Infect Dis (1999) 1.03
Fcgamma receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse. Arthritis Rheum (1999) 1.02
Fc receptor and complement receptor-mediated phagocytosis in host defence. Curr Opin Infect Dis (1998) 1.02
The human low affinity immunoglobulin G Fc receptor IIC gene is a result of an unequal crossover event. J Biol Chem (1993) 1.01
Human T cell clones exerting multiple cytolytic activities show heterogeneity in susceptibility to inhibition by monoclonal antibodies. J Immunol (1984) 1.01
Interaction between hybrid mouse monoclonal antibodies and the human high-affinity IgG FcR, huFc gamma RI, on U937. Involvement of only one of the mIgG heavy chains in receptor binding. J Immunol (1989) 1.01
Human Fc gamma receptor II: a standby receptor activated by proteolysis? Immunol Today (1990) 1.01
Fcgamma receptor polymorphisms in systemic lupus erythematosus: association with disease and in vivo clearance of immune complexes. Arthritis Rheum (2000) 1.00
Comparison of typing methods for Clostridium difficile isolates. J Clin Microbiol (1993) 1.00
Invasive group A streptococcal disease in the Netherlands: evidence for a protective role of anti-exotoxin A antibodies. J Infect Dis (2000) 0.99
Human low-affinity IgG receptor Fc gamma RIIa (CD32) introduced into mouse fibroblasts mediates phagocytosis of sensitized erythrocytes. Blood (1992) 0.99
Association of human Fc gamma RIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease. Clin Infect Dis (1998) 0.98
Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. J Immunol (2000) 0.98
Effective phagocytosis and killing of Candida albicans via targeting FcgammaRI (CD64) or FcalphaRI (CD89) on neutrophils. J Infect Dis (1999) 0.98
HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood (1996) 0.97
Granulocyte colony-stimulating factor induces hFc gamma RI (CD64 antigen)-positive neutrophils via an effect on myeloid precursor cells. Blood (1993) 0.97
Characterization of natural killer (NK) cells and killer (K) cells in human blood: discrimination between NK and K cell activities. Eur J Immunol (1978) 0.97
Fcgamma receptor IIa polymorphism in Caucasian patients with systemic lupus erythematosus: association with clinical symptoms. Arthritis Rheum (1998) 0.97
Lysis of tumor cells by CD3+4-8-16+ T cell receptor alpha beta- clones, regulated via CD3 and CD16 activation sites, recombinant interleukin 2, and interferon beta 1. J Immunol (1987) 0.96
Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer. J Immunother (1991) (1992) 0.96
CR3 (alphaM beta2; CD11b/CD18) restores IgG-dependent phagocytosis in transfectants expressing a phagocytosis-defective Fc gammaRIIA (CD32) tail-minus mutant. J Immunol (1996) 0.96
Pneumococcal capsular polysaccharide-specific IgA triggers efficient neutrophil effector functions via FcalphaRI (CD89). J Infect Dis (2000) 0.95
The human Fc receptor for IgA (Fc alpha RI, CD89) on transgenic peritoneal macrophages triggers phagocytosis and tumor cell lysis. Immunol Lett (1999) 0.95
A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes. Gene Ther (1998) 0.95
Multiplex screening for functionally rearranged immunoglobulin variable regions reveals expression of hybridoma-specific aberrant V-genes. J Immunol Methods (2001) 0.95
Rapid expansion of human cytotoxic T cell clones: growth promotion by a heat-labile serum component and by various types of feeder cells. J Immunol Methods (1984) 0.94
Meningococcal disease and polymorphism of FcgammaRIIa (CD32) in late complement component-deficient individuals. Clin Exp Immunol (1998) 0.94
Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol (1996) 0.94
Immunoglobulin-binding sites of human FcalphaRI (CD89) and bovine Fcgamma2R are located in their membrane-distal extracellular domains. J Exp Med (1999) 0.94
Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells. Cancer Res (1998) 0.93
Immunogenic properties of octasaccharide-protein conjugates derived from Klebsiella serotype 11 capsular polysaccharide. Infect Immun (1985) 0.93
Human IgG Fc receptors. Int Rev Immunol (1997) 0.93
FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood (1997) 0.93
Assessment of complement-mediated killing of Moraxella (Branhamella) catarrhalis isolates by a simple method. Clin Diagn Lab Immunol (1995) 0.92
Phage antibodies obtained by competitive selection on complement-resistant Moraxella (Branhamella) catarrhalis recognize the high-molecular-weight outer membrane protein. Infect Immun (1998) 0.92